
|Articles|April 15, 2007
Newly formed Opko Corp. plans to study wet AMD therapy
Newly formed Opko Corp. plans a phase III trial of bevasiranib (formerly Cand5) as maintenance therapy for wet AMD in combination with ranibizumab (Lucentis, Genentech).
Advertisement
Key Points
Miami-Two privately owned pharmaceutical companies will merge with a publicly traded company with no active operations to create Opko Corp.
The company unites Acuity Pharmaceuticals and Froptix Corp. with eXegenics Inc. Headquarters will be in Miami.
Philip Frost, former chief executive officer (CEO) and chairman of IVAX Corp., will become chairman and CEO of Opko.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
FDA approves NDA labeling supplement allowing re-administration of iDose TR
4
FDA Type C meeting supports phase 2b/3 pathway for urcosimod in neuropathic corneal pain
5



























